Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide-Reference-Cited by-同舟云学术

Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide

Author:

Knudsen Jakob Schöllhammer¹^ORCID,Thomsen Reimar Wernich¹^ORCID,Pottegård Anton²,Knop Filip Krag³⁴,Sørensen Henrik Toft¹

Affiliation:

1. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

2. Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark

3. Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, University of Copenhagen, Gentofte, Denmark

4. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

Reference4 articles.

3. Data resource profile: the Danish National Prescription Registry;Pottegård;Int J Epidemiol,2017

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献